2QCY2011 Result Update | Pharmaceutical

July 29, 2011

Aventis Pharma
Performance Highlights

REDUCE
CMP Target Price
Investment Period
Stock Info Sector Market Cap (`cr) Beta 52 Week High / Low Avg. Daily Volume Face Value (`) BSE Sensex Nifty Reuters Code Bloomberg Code Pharmaceutical 4,846 0.3 2380/1710 3023 10 18,197 5,482 AVPH.BO AVEN@IN
276 38 44 51 10 (5) 1 (2) 272 25 44 42 11.5 42.7 0.7 17.2

`2,091 `1,937
-

Y/E Dec. (` cr) Net sales Other income Operating profit Net profit

2QCY2011 1QCY2011 % chg (qoq) 2QCY2010 % chg (yoy) 303 36.1 44 50

Source: Company, Angel Research

For 2QCY2011, Aventis Pharma (Aventis) reported in-line results at the top-line and net profit front, led by growth across the domestic market. Domestic sales grew by 12.1%, contributing around 80% to the total revenue; the remaining contribution came in from exports, which grew by 9.3% in 2QCY2s011. The company incurred planned expenditure in two of its critical projects (Prayas, a project to deliver high-quality, low-cost healthcare to the rural population; and entry into the over-the-counter (OTC) market). These projects are slated to be the future growth drivers for the company. Given the valuations, we recommend a Reduce rating on the stock. Revenue growth led by the domestic segment: Aventis net sales grew by 11.5% yoy to `303cr (`272cr) for the quarter, in-line with our estimates of `299cr, backed by 12.1% growth in the domestic segment. Export sales grew by 9.3% to `58.8cr. The company reported gross margin of 50.6% (49.6%), in-line with our estimates of 50.7%. OPM came in at 14.5% (16.0%), lower than our estimates of 16.0% for the quarter. Net profit came in at `49.7cr (`53.0cr), up 17.2% yoy, lower than our estimates of `53cr. Outlook and valuation: We expect net sales to post a 13.6% CAGR to `1,401cr and EPS to register a 15.6% CAGR to `89.7cr over CY201012E. At current levels, the stock is trading at 24.6x and 23.5x CY2011E and CY2012E earnings, respectively. We recommend Reduce on the stock with a target price of `1,937. Key financials
Y E Dec. (`cr) Net sales % chg Adj.net profit % chg EPS (`) EBITDA (%) P/E (x) RoE (%) RoCE (%) P/BV (x) EV/Sales (x) EV/EBITDA (x)
Source: Company, Angel Research

Shareholding Pattern (%) Promoters MF / Banks / Indian Fls FII / NRIs / OCBs Indian Public / Others 60.4 23.9 9.9 5.8

Abs. (%) Sensex Aventis

3m (4.9) 4.9

1yr 1.1 10.1

3yr 31.9 173.4

CY2009 974 (0.9) 157.4 (5.3) 68.4 15.2 30.8 17.9 14.8 5.2 4.4 28.8

CY2010 1,085 11.3 155.0 (1.5) 67.3 13.2 31.3 15.9 12.6 4.8 3.9 29.3

CY2011E 1,224 12.8 197.0 27.1 85.5 14.9 24.6 18.3 14.8 4.2 3.4 22.9

CY2012E 1,401 14.4 206.4 4.8 89.7 15.3 23.5 17.1 15.7 3.8 2.9 19.0

Sarabjit Kour Nangra

+91 22 3935 7800 Ext: 6806 sarabjit@angelbroking.com

Please refer to important disclosures at the end of this report

Aventis Pharma | 2QCY2011 Result Update

Exhibit 1: 2QCY2011 performance

Y/E Dec. (` cr) Net sales Other income Total income PBIDT OPM (%) Interest Depreciation & amortisation PBT & exceptional items Less : Exceptional items Profit before tax Provision for taxation Adj net profit EPS (`)
Source: Company, Angel Research

2QCY2011 303 36 339 44 14.5 0.0 5 75 0 75 24 50 21.6

1QCY2011 276 38 314 44 15.7 0 5 76 0 76 25 51 12.7

% chg (qoq) 9.6 (4.7) 7.9 0.7

1QCY2010 272 25 297 44 16.0 0

% chg (yoy) 1HCY2011 1HCY2010 11.5 42.7 14.2 0.7 579 74 653 87 15.1 0 14.9 16.2 16.2 9.7 17.2 11 150 0 150 49 101 40.0 523 48 571 80 15.3 0 9 119 0 119 40 79 31.0

% chg yoy 10.7 54.5 14.4 9.3

0.0 (1.7) (1.7) (5.6) (1.8)

5 64 0 64 22 42 18.4

20.0 26.5 26.5 21.6 29.0

Exhibit 2: 2QCY2011 Actual vs. Angel estimates

` cr Net sales Other income Operating profit Tax Net profit
Source: Company, Angel Research

Actual 303 36 44 24 50

Estimates 299 38 48 27 53

Variation (%) 1.2 (4.7) (8.7) (12.5) (6.3)

Revenue growth led by the domestic segment: Aventis net sales grew by 11.5%

yoy to `303cr (`272cr) for the quarter, in-line with our estimates of `299cr, backed by 12.1% growth in the domestic segment. Export sales during the quarter grew by 9.3% to `58.8cr. The company incurred planned expenditure in two of its critical projects Prayas and entry into the OTC market. These projects are slated to be the future growth drivers for the company.

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Exhibit 3: Sales trend

300 250 200 197 218 232 224 222 244 25 20 15 10 5

(` cr)

150 100 50 0 (50) (100)

1QCY2010 2QCY2010 3QCY2010 4QCY2010 1QCY2011 2QCY2011

(%)

54

54

44

63

54

59

0 (5) (10) (15) (20) (25)

Domestic

Export

Source: Company, Angel Research

OPM increased by 156bp yoy: Aventis reported gross margin of 50.6% (49.6%), in-line with our estimates of 50.7% for the quarter. OPM came in at 14.5% (16.0%) for the quarter on account of 8.1% and 29.6% growth in employee and other expenses at `44.1cr (`40.8cr) and `65.3cr (`50.4cr), respectively.

Exhibit 4: OPM trend

18.0 15.0 14.5 12.0 16.0 15.4 15.7 14.5

(%)

9.0 6.0 3.0 0.0 1QCY2010 2QCY2010 3QCY2010 4QCY2010 1QCY2011 2QCY2011 7.2

Source: Company, Angel Research

Bottom line below estimates: For the quarter, Aventis reported net profit of `49.7cr (`42.4cr), up 17.2% yoy, and lower than our estimate of `53cr, led by lower-thanexpected OPM.

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Exhibit 5: Net profit trend

60 50 40 30 20 10 0 1QCY2010 2QCY2010 3Q CY2010 4Q CY2010 1QCY2011 2QCY2011 36 29 47 42 51 50

Source: Company, Angel Research

Recommendation rationale
Focus on top-line growth: Aventis recorded a revenue CAGR of 5.3% to `1,085cr over CY200610 on the back of slower-than-expected growth on the domestic formulation front and loss of distribution rights of Rabipur vaccine. Going forward, to grow in-line with the industrys average in the domestic segment, Aventis has rolled out its Prayas project, an initiative to increase its penetration in rural areas. Under the project, the company would launch low-price products in the anti-infective and NSAID therapeutic segments and increase its field force. The project is expected to provide incremental revenue of `500cr over the next five years. Aventis also plans to launch CVS and vaccine products in the domestic market post the acquisition of Shantha Biotech by its parent company. We expect the companys net sales to log a 13.6% CAGR over CY201012E, majorly driven by its domestic formulation sales. Valuation: Aventis has a strong balance sheet with cash of `655cr (~14% of market cap, as of CY2010), which could be used for future acquisitions or higher dividend payouts. We expect net sales to post a 13.6% CAGR to `1,401cr and EPS to register a 15.6% CAGR to `89.7cr over CY201012E. At current levels, the stock is trading at 24.6x and 23.5x CY2011E and CY2012E earnings, respectively. We recommend a Reduce rating on the stock with a target price of `1,937.

Exhibit 6: Key assumptions

CY2011E Net sales growth (%) Domestic sales growth (%) Export sales growth (%) Growth in employee expenses (%) Operating margins (%) Net profit growth (%) Capex (` cr)
Source: Company, Angel Research

CY2012E 14.4 15.0 12.0 15.0 15.3 5.1 21.0

12.8 14.0 8.0 16.0 14.9 27.1 26.6

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Exhibit 7: One-year forward P/E

2,500 2,000 1,500
(`)

1,000 500 0
Apr-07 Apr-08 Apr-09 Apr-10 Apr-11 Jul-07 Jul-08 Jul-09 Jul-10 Oct-07 Oct-08 Oct-09 Oct-10 Jan-07 Jan-08 Jan-09 Jan-10 Jan-11 Jul-11

10x
Source: Company, Angel Research

15x

20x

25x

Exhibit 8: Recommendation summary

Company Aurobindo Pharma Aventis* Cadila Healthcare Cipla Dr Reddy's Dishman Pharma GSK Pharma* Indoco Remedies Ipca labs Lupin Orchid Chemicals Ranbaxy* Sun Pharma Reco Buy Reduce Buy Buy Buy Buy Neutral Buy Accumulate Buy Buy Accumulate Neutral CMP Tgt. price (`) 171 2,104 884 308 1,588 90 2,346 421 328 455 206 539 517 (`) 278 1937 1,053 377 1,920 133 658 358 593 373 593 Upside % PE (x) 62.2 (7.9) 19.2 22.5 20.9 48.4 56.2 9.1 30.4 80.8 10.0 9.0 23.4 17.2 16.3 16.5 7.7 27.0 6.4 11.9 15.3 5.5 12.0 22.0 FY2013E EV/Sales (x) 1.2 2.9 2.7 3.0 2.9 1.3 6.3 0.8 1.8 2.5 1.3 1.7 5.5 EV/EBITDA (x) 6.8 19.0 13.6 14.0 11.4 7.4 17.6 4.9 8.3 12.8 5.9 7.4 17.6 FY11-13E CAGR in EPS (%) 29.5 15.6 21.6 25.2 22.7 8.6 14.6 25.8 14.8 24.0 29.6 31.8 15.8 FY2013E RoCE (%) 13.8 15.8 28.3 17.0 22.0 7.4 41.0 17.6 23.3 23.9 11.7 26.8 20.2 RoE (%) 19.0 17.1 35.2 18.5 25.2 9.2 30.7 19.3 24.9 30.8 23.4 25.9 20.4

Source: Company, Angel Research; Note: *December year end

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Profit & loss statement

Y/E Dec. (`cr) Net sales Other operating income Total operating income % chg Total expenditure Net raw materials Other mfg costs Personnel Other EBITDA % chg (% of Net sales) Depreciation& amortisation EBIT % chg (% of Net sales) Interest & other charges Other income (% of PBT) Recurring PBT % chg PBT (reported) Tax (% of PBT) PAT (reported) Extra-ordinary items PAT after MI (reported) ADJ. PAT % chg (% of Net sales) Basic EPS (`) Fully Diluted EPS (`) % chg 144 144 (14.7) 16.5 63 63 (14.7) 166 166 15.1 16.9 72 72 15.1 157 157 (5.3) 16.2 68 68 (5.2) CY2007 CY2008 CY2009 CY2010 CY2011E CY2012E 874 23 896 1.2 705 423 17 104 162 168 (23.7) 19.3 19 149 (26.5) 17.1 0.2 51 23.0 223 (10.8) 222.8 78.4 35.2 144 983 36 1,019 13.7 798 476 41 119 161 186 10.2 18.9 18 167 12.2 17.0 0.3 57 21.8 260 16.5 260 93.3 36.0 166 974 52 1,027 0.7 827 482 45 144 156 148 (20.4) 15.2 17 130 (22.1) 13.4 0.1 59 24.3 241 (7.0) 241 84.0 34.8 157 1,085 59 1,144 11.4 942 539 53 163 187 143 (3.1) 13.2 21 123 (6.0) 11.3 2.9 55 23.4 233 (3.4) 234 79.0 33.8 155 75.7 231 155 (1.5) 21.3 67 67 (1.6) 1,224 58 1,282 12.1 1,042 569 61 189 222 182 27.0 14.9 22 160 30.2 13.0 62 22.1 280 19.9 280 82.6 29.6 197 197 197 27.1 16.1 86 86 27.1 1,401 50 1,450 13.1 1,187 644 70 218 254 214 17.7 15.3 24 190 19.1 13.6 0 59 19.7 299 6.9 299 92.4 30.9 206 206 206 4.8 14.7 90 90 4.8

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Balance sheet
Y/E Dec. (` cr) SOURCES OF FUNDS Equity share capital Reserves & surplus Shareholders funds Total loans Total liabilities APPLICATION OF FUNDS Gross block Less: Acc. depreciation Net block Capital Work-in-Progress Investments Current assets Cash Loans & advances Other Current liabilities Net current assets Deferred tax assets Total assets 304 169 136 9 5 754 391 125 238 210 544 13 707 321 178 143 6 5.2 896 497 136 262 236 660 15 829 335 190 145 27 5.2 1,014 586 144 284 274 740 15 932 375 204 171 13 0.4 1,214 655 257 302 394 820 10 1,014 396 227 170 13 0.4 1,149 677 115 357 207 942 17 1,142 417 250 167 13 0.4 1,300 780 132 389 225 1,076 20 1,277 23 684 707 707 23 806 829 829 23 909 932 932 23 991 1,014 1,014 23 1,119 1,142 1,142 23 1,253 1,277 1,277 CY2007 CY2008 CY2009 CY2010 CY2011E CY2012E

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Cash flow statement

Y/E Dec. (` cr) Profit before tax Depreciation (Inc)/Dec in Working Capital Less: Other income Direct taxes paid Cash Flow from Operations (Inc.)/Dec.in Fixed Assets (Inc.)/Dec. in Investments Other income Cash Flow from Investing Issue of Equity Inc./(Dec.) in loans Dividend Paid (Incl. Tax) Others Cash Flow from Financing Inc./(Dec.) in Cash Opening Cash balances Closing Cash balances CY2007 CY2008 CY2009 CY2010 CY2011E CY2012E 223 18 (4) 23 97 117 (18) 23 5 (84) (33) (117) 5 386 391 260 18 (21) 36 98 123 (24) 0 36 12 (43) 15 (28) 107 391 497 241 17 4 52 92 118 (41) 52 11 (43) 2 (41) 88 497 586 234 21 (10) 59 79 107 (27) (5) 59 27 (55) (9) (64) 69 586 655 280 22 (101) 58 89 53 (21) 0 58 37 (69) (69) 21 655 677 299 24 (31) 50 96 147 (21) 50 29 (72) (0) (72) 103 677 780

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Key ratios
Y/E Dec. Valuation Ratio (x) P/E (on FDEPS) P/CEPS P/BV Dividend yield (%) EV/Sales EV/EBITDA EV / Total Assets Per Share Data (`) EPS (Basic) EPS (fully diluted) Cash EPS DPS Book Value Returns (%) RoCE (Pre-tax) Angel ROIC (Pre-tax) ROE Turnover ratios (x) Asset Turnover (Gross Block) Inventory / Sales (days) Receivables (days) Payables (days) WC cycle (ex-cash) (days) Solvency ratios (x) Net debt to equity Net debt to EBITDA (0.6) (2.3) (0.6) (2.7) (0.6) (4.0) (0.6) (4.6) (0.6) (3.7) (0.6) (3.6) 3.0 69 26 47 43 3.3 63 26 46 56 3.1 72 25 49 56 3.2 75 18 47 51 3.3 73 20 41 61 3.6 70 24 36 71 22.7 57.8 22.0 21.8 52.9 21.6 14.8 40.5 17.9 12.6 36.9 15.9 14.8 40.1 18.3 15.7 40.7 17.1 62.7 62.7 71.1 27.6 306.9 72.2 72.2 80.1 16.0 360.0 68.4 68.4 75.9 20.0 404.6 67.3 67.3 109.1 55.0 440.3 85.5 85.5 95.2 25.7 495.9 89.7 89.7 100.0 26.9 554.5 33.6 29.6 6.9 1.3 5.1 26.5 6.3 29.2 26.3 5.8 0.8 4.4 23.4 5.2 30.8 27.7 5.2 1.0 4.4 28.8 4.6 31.3 19.3 4.8 2.6 3.9 29.3 4.1 24.6 22.1 4.2 1.2 3.4 22.9 3.7 23.5 21.0 3.8 1.3 2.9 19.0 3.2 CY2007 CY2008 CY2009 CY2010 CY2011E CY2012E

July 29, 2011

Aventis Pharma | 2QCY2011 Result Update

Research Team Tel: 022 - 3935 7800

E-mail: research@angelbroking.com

Website: www.angelbroking.com

DISCLAIMER This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Angel Broking Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavours to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Angel Broking Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past. Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Note: Please refer to the important `Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Limited and its affiliates may have investment positions in the stocks recommended in this report.

Disclosure of Interest Statement 1. Analyst ownership of the stock 2. Angel and its Group companies ownership of the stock 3. Angel and its Group companies' Directors ownership of the stock 4. Broking relationship with company covered

Aventis Pharma No No No No

Note: We have not considered any Exposure below ` 1 lakh for Angel, its Group companies and Directors.

Ratings (Returns):

Buy (> 15%) Reduce (-5% to 15%)

Accumulate (5% to 15%) Sell (< -15%)

Neutral (-5 to 5%)

July 29, 2011

10